Matt Kaeberlein

Background

Matt Kaeberlein is a geroscientist who spent many years at the University of Washington, where he co-directed the Healthy Aging and Longevity Research Institute, and now leads Optispan Health. His training spans yeast genetics, mTOR biology, and translational geroscience.

Lines of work

• mTOR / rapamycin biology — mechanistic and translational characterisation of mTOR inhibition as an intervention to slow aging.
• Dog Aging Project — a large longitudinal cohort study of companion dogs that includes the TRIAD randomised trial of rapamycin in pet dogs. Dogs share the human environment and develop many of the same age-related diseases.
• Companion-animal geroscience more broadly — framing pet aging studies as a translational bridge between rodent and human.
• Public advocacy for treating aging as a modifiable target, including the “Targeting Aging” framework.

Public profile

Active podcast guest and public communicator who often pushes back against overstated longevity claims while remaining a strong advocate for the underlying science. Hosts the Optispan podcast.

Related entries

See also: Rapamycin, PEARL trial, Disabled macroautophagy.